Employees: 5,025
Size Sunflower Pharmaceutical (002737.SZ) is a China Health Care company (Pharmaceuticals: Major) with a market value of $1.04B, the 2097th largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥12.01 on 18 Nov 2026.
Performance Over six months the shares fell 11.0%, against -11.0% for the median peer and -20.0% for the China market (cap-weighted) — 11th highest of 21 in its peer set.
Growth Revenue grew 31.4% over the last twelve months (peer median +3.9%); the operating margin is -7.2% (peer median 8.6%).
Valuation It trades at 4.7× forward earnings against a peer median of 16.9× (2nd cheapest of 14).
Price implies For today's price to make sense, revenue must grow about -7% a year for seven years (Req g). Recent delivered growth is -8%, so the hurdle is +1 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
Capital Return on invested capital runs 8.1 points below its cost of capital (5.0% WACC).
Next results Next results expected around 22 Apr 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥2.75B | CN¥2.30B | CN¥3.35B | CN¥5.66B | CN¥5.05B |
| Revenue growth | — | -31% | -41% | +12% | — |
| Gross profit | CN¥1.49B | CN¥807M | CN¥1.44B | CN¥3.10B | CN¥2.84B |
| EBITDA | n/a | -CN¥118M | CN¥639M | CN¥1.36B | CN¥1.29B |
| Net income | -CN¥141M | -CN¥258M | CN¥492M | CN¥1.12B | CN¥867M |
| Free cash flow | CN¥359M | CN¥514M | -CN¥366M | CN¥774M | CN¥1.84B |
| Capital expenditure | CN¥106M | CN¥96.1M | CN¥92.8M | CN¥149M | CN¥153M |
| Total debt | CN¥299M | CN¥151M | CN¥10.2M | CN¥30.1M | CN¥436M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 002737.SZ | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +6.8% | -8.3% | 2nd highest of 21 |
| 6-month return | -11.0% | -11.0% | 11th highest of 21 |
| Distance from 52-week high | -22.1% | -32.1% | 5th highest of 21 |
| Revenue growth (TTM) | +31.4% | +3.9% | 4th highest of 19 |
| Operating margin | -7.2% | 8.6% | 4th lowest of 20 |
| Forward P/E | 4.7× | 16.9× | 2nd cheapest of 14 |
| Growth the price implies (Req g, 7 yrs) | -6.5% | 2.5% | 2nd least demanding of 14 |
| Growth delivered (Del g) | -7.7% | +6.5% | 2nd lowest of 14 |
| Hurdle (Req g minus delivered) | +1.1 pp | -3.3 pp | 5th most demanding of 14 |
| ROIC minus cost of capital | -8.1 pp | +0.4 pp | 3rd lowest of 18 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Sunflower Pharmaceutical 002737.SZ | China | $1.04B | -11% | +31% | -7% | 4.7× | -6.5% | -7.7% |
| Towa Pharmaceutical 4553.T | Japan | $1.03B | -10% | +7% | 9% | 7.7× | -0.3% | +12.1% |
| Savara SVRA | United States | $1.04B | -7% | n/a | n/a | n/a | n/a | n/a |
| Basilea Pharmaceutica BSLN.SW | Switzerland | $1.04B | +33% | +5% | 24% | 10.5× | -5.6% | +12.7% |
| Chengdu Easton Biopharmaceuticals 688513.SS | China | $1.03B | -33% | -2% | 13% | 24.6× | 4.4% | +7.7% |
| Shandong Lukang Pharmaceutical 600789.SS | China | $1.05B | -18% | -7% | 3% | n/a | 2.5% | +6.5% |
| Jiangxi Fushine Pharmaceutical 300497.SZ | China | $1.02B | -23% | +103% | 24% | 9.9× | 7.5% | -4.5% |
| Blue Jet Healthcare BLUEJET.NS | India | $1.05B | +19% | -7% | 28% | 30.6× | 40.8% | +13.8% |
| Everest Medicines 1952.HK | Hong Kong | $1.05B | -20% | +193% | -5% | 23.2× | n/a | n/a |
| Zhejiang Tianyu Pharmaceutical 300702.SZ | China | $1.02B | +1% | +27% | 4% | 21.4× | 4.3% | +3.5% |
| Renhe Pharmacy 000650.SZ | China | $1.01B | -12% | -7% | 14% | 16.9× | -10.7% | -7.0% |
| SAWAI 4887.T | Japan | $1.01B | -18% | +2% | 9% | 12.0× | n/a | n/a |
| Shanghai Yizhong Pharmaceutical 688091.SS | China | $1.00B | -49% | +32% | 14% | n/a | n/a | n/a |
| Aurisco Pharmaceutical 605116.SS | China | $1.00B | -23% | +3% | 25% | 13.6× | -2.0% | +18.7% |
| Shanghai InnoStar Bio-tech 688710.SS | China | $1,000M | +17% | +24% | 6% | 59.3× | 12.7% | +19.4% |
| Omeros OMER | United States | $1.08B | +24% | n/a | -56% | 4.3× | n/a | n/a |
| North China Pharmaceutical 600812.SS | China | $1.08B | -12% | -21% | 5% | n/a | 1.0% | -4.2% |
| Jiangsu Kanion Pharmaceutical 600557.SS | China | $989M | -9% | +8% | 7% | 19.8× | 2.3% | +1.8% |
| Aarti Pharmalabs AARTIPHARM.NS | India | $984M | +44% | +13% | 18% | n/a | n/a | n/a |
| MedinCell MEDCL.PA | France | $1.09B | +4% | -23% | -131% | n/a | n/a | n/a |
| InventisBio 688382.SS | China | $982M | -47% | -61% | -563% | n/a | 6.5% | -60.6% |